LAS VEGAS, NEVADA, November 18, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced that its 50/50 joint venture (Klothonova) with Austrianova has entered into an exclusive, worldwide License Agreement with Klothea Bio, Inc. The license agreement, effective immediately, grants Klothonova exclusive global rights to develop, manufacture, and commercialize Klothea Bio’s proprietary Klotho producing cells, encapsulated using Austrianova’s proprietary Cell-in-a-Box® technology, for the treatment of diseases and conditions in humans and animals.
Under the terms of the agreement, Klothea Bio—a Delaware-based biotechnology company specializing in Klotho protein research and therapeutic applications—provides Klothonova access to a proprietary Klotho generating cell line.
Klotho, often referred to as the “longevity protein,” has demonstrated significant potential in combating key drivers of aging such as cellular senescence and chronic inflammation. The collaboration aims to accelerate the development of regenerative and anti-aging therapies that target the cellular mechanisms underlying longevity and chronic disease, positioning Klotho-based treatments at the forefront of next-generation anti-aging innovations.
Under the agreement, Klothonova will leverage this technology in conjunction with Austrianova’s proprietary Cell-in-a-Box® encapsulation platform to encapsulate Klothea’s genetically modified cell line that overexpresses Klotho proteins. This aims to create encapsulated, implantable therapies capable of sustained, localized delivery, enhancing safety and efficacy for applications in regenerative medicine and disease prevention.
“This license represents a pivotal milestone for Klothonova and underscores Avant’s commitment to transforming biotech innovation into real-world impact,” said Avant Technologies CEO, Chris Winter. “By combining Klothea’s cutting-edge Klotho expertise with our joint venture’s advanced cell encapsulation technology, we’re poised to pioneer therapies that could redefine healthy aging and extend quality of life for millions.”
The Field of Use encompasses the treatment of a wide array of diseases and conditions, enabling Klothonova to pursue comprehensive development programs from preclinical research through commercialization. Key terms in the agreement include milestone payments tied to development and regulatory achievements, as well as royalties on net sales, ensuring aligned incentives for rapid advancement.
This agreement builds on the September 2025 formation of Klothonova as a joint venture between Avant Technologies and Austrianova, which was established to focus on Klotho-based cell therapies. Since its launch in October 2025, Klothonova has initiated the preparatory work needed for GMP-manufacturing of the encapsulated Klotho-overexpressing cell line, with plans to advance into IND-enabling studies in the coming year.
About Avant Technologies
Avant Technologies, Inc. is an emerging biotechnology company focused on identifying genetically modified cells lines, and through joint venture and licensing agreements developing innovative cell-based therapies.
About Klothonova
Klothonova is a 50/50 joint venture between Avant Technologies and Austrianova, focused on developing novel cell-based therapies utilizing the Klotho protein for age-related conditions. Headquartered in Las Vegas, Nevada, Klothonova combines expertise in genetic engineering, cell encapsulation, and therapeutic delivery to pioneer sustainable, long-acting treatments.
Forward-Looking Statements
This release includes forward-looking statements regarding Austrianova (the Company) and its respective businesses. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this release, including completion of the public offering, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks affecting the Company, economic factors and the equity markets generally. No forwardlooking statement can be guaranteed. Except as required by applicable securities laws, forwardlooking statements speak only as of the date on which they are made and Austrianova undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. This is not an offer or solicitation to buy or sell any securities.
Brian Salmons
SGAustria
About Austrianova
Austrianova, (www.austrianova.com) part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated human or animal cells from rejection by the immune system and allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop a wide range of standard cells as one-for-all living pharmaceuticals. Bac-in-a-Box® is a similar protective device adapted for encapsulation of bacteria and yeast, including probiotics, and has both human food as well as animal feed applications due to its ability to extend storage under lyophilized conditions and to protect encapsulated bacteria against destruction by stomach acid. Austrianova now also offers GMP4Cells that includes competitively priced Master Cell Bank and Working Cell Bank production as well as “Fill and Finish” services for cell therapy products (such as stem cell therapies, biologics produced from cells e.g. vaccines, antibodies, recombinant proteins etc).